<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536637</url>
  </required_header>
  <id_info>
    <org_study_id>DMT310-001</org_study_id>
    <nct_id>NCT03536637</nct_id>
  </id_info>
  <brief_title>DMT310-001 Topical in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Study of Tolerability, Safety, And Efficacy, of DMT310 In Patients With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermata Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermata Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder
      mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 21, 2018</start_date>
  <completion_date type="Anticipated">February 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Inflammatory and Noninflammatory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by Investigator Global Assessment (IGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>0 None No evidence of facial acne vulgaris
Minimal Few noninflammatory lesions (comedones) are present; a few inflammatory lesions(papules/pustules) may be present; no nodulo-cystic lesions are allowed)
Mild Several to many noninflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) are present; no nodulo-cystic lesions are allowed
Moderate Many noninflammatory (comedones) and inflammatory lesions (papules/pustules) are present; no nodulo-cystic lesions are allowed
Severe Significant degree of inflammatory disease; papules/pustules are a predominant feature; a few nodulo-cystic lesions may be present; comedones may be present</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMT310 Powder mixed with Hydrogen Peroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMT310 Powder mixed with Placebo Diluent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo powder mixed with Hydrogen Peroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo powder mixed with Placebo Diluent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMT310</intervention_name>
    <description>Topical Powder</description>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_label>Study Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrogen Peroxide</intervention_name>
    <description>Liquid Diluent</description>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_label>Study Treatment 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Topical Powder</description>
    <arm_group_label>Study Treatment 3</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or non-pregnant female at least 18 years of age.

          -  Clinical diagnosis of moderate to severe acne vulgaris as determined by:

        Investigator's Global Assessment (IGA) at Randomization Patient has at least 20 but not
        more than 50 inflammatory lesions on the face Patient has at least 20 but not more than 100
        noninflammatory lesions on the face

          -  Patient is willing to apply the Investigational Product as directed

          -  Patient is willing and able to comply with the protocol

        Exclusion Criteria:

          -  Patient is pregnant or planning to become pregnant

          -  Patient is taking a topical therapy on the face which may affect the patient's acne
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dermata Sr. Vice President of Development</last_name>
    <phone>(858) 223-0883</phone>
    <email>cnardo@dermatarx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Tennessee</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrogen Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

